Skip to main content

Table 1 Solicited adverse events after vaccinations at each dose in the study subjects (safety population)

From: Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial

  Group (n) No. (%) of subjects p -value*
AE no AE
Total KD-287 (102) 87 (85.29) 15 (14.71) 0.050
JEV-GCC (102) 77 (75.49) 25 (24.51)
After 1st Vaccination KD-287 (102) 65 (63.73) 37 (36.27) 0.118
JEV-GCC (102) 54 (52.94) 48 (47.06)
After 2nd Vaccination KD-287 (102) 45 (44.12) 57 (55.88) 0.900
JEV-GCC (100) 45 (45.00) 55 (55.00)
After 3rd Vaccination KD-287 (100) 46 (46.00) 54 (54.00) 0.394
JEV-GCC (96) 50 (52.08) 46 (47.92)
  1. AE, adverse event.
  2. *The p-value was calculated using the chi-square test.